At the same time, individual mood changes during treatment are real and worth taking seriously
When Novo Nordisk faced production issues, choosing Eli Lilly's Mounjaro and Zepbound over Novo Nordisk's Wagovy became easier
Members receive hour-by-hour personalized guidance to change their behavior based on their response to food, sleep, activity, and stress
Four states dropped coverage in late 2025: California, New Hampshire, Pennsylvania , and South Carolina all eliminated Medicaid coverage of GLP-1s for obesity treatment reducing the national count from 16 states to 13
Many people report feeling satisfied with much smaller portions than before
Clinical trials show body weight reductions that surpass anything weve seen from current GLP-1 medications